此配图应该有数字的,请补上 * * * The aprepitant triple-therapy is recommended for the acute phase of HEC, and the two combination including aprepitant for the delayed phase of HEC. These recommendation also suitable for the high risk MEC pts, who are receiving certain chemotherapy drugs, such as carbopaltin, cisplatin, doxorubicin, epirubicin, ifosfamide, irinotecan, or methotrexate, etc. The detailed information would be introduced in the medical MAP. Recent guidelines published incorporate recommendations for the use of EMEND and the newest 5-HT3 RA, palonosetron. Slide 15 presents the recommended trea
原创力文档

文档评论(0)